Logo image
Lipid-lowering treatment for secondary prevention of peripheral arterial occlusive disease Influence of the new guidelines of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS)
Journal article   Peer reviewed

Lipid-lowering treatment for secondary prevention of peripheral arterial occlusive disease Influence of the new guidelines of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS)

J. F. Dopheide and H. Drexel
Gefässchirurgie, v 25(3), pp 160-165
01 May 2020

Abstract

Cardiovascular System & Cardiology Life Sciences & Biomedicine Peripheral Vascular Disease Science & Technology
In addition to arterial hypertension, smoking and diabetes mellitus, dyslipidemia is one of the primary risk factors that significantly influence the development and progress of peripheral arterial occlusive disease (PAOD). The treatment of dyslipidemia is of crucial importance, especially for lowering of low-density lipoprotein cholesterol (LDL-C) levels, which has been accentuated once again in the current guidelines of the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS).

Metrics

5 Record Views
4 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Peripheral Vascular Disease
Logo image